Purpose : To assess the safety and tolerability of BI 836880, a dual vascular endothelial growth factor (VEGF)/angiopoietin-2 inhibitor, in a two-part single rising dose (SRD) and multiple rising dose (MRD) study in patients with wet age-related macular degeneration (wAMD). Methods : This...